Drug does not appear to reduce risk of heart attack or death following CABG surgery

Use of MC-1 (a naturally occurring metabolite of vitamin B6) before and for 30 days after coronary artery bypass graft surgery did not reduce the risk of heart attack or cardiovascular death, according to a JAMA study being released early online April 1 to coincide with its presentation at the annual conference of the American College of Cardiology. The study will be published in the April 16 issue of JAMA.

“Coronary artery bypass graft (CABG) surgery is one of the most important therapeutic options for relieving angina and improving survival and quality of life in patients with multivessel coronary artery disease. It is the most commonly performed cardiac surgical procedure in the world, and in 2005, more than 250,000 CABG procedures were performed in the United States,” the authors write. Serious complications can include heart attack, recurrent angina, kidney insufficiency, stroke, and death. Phase 2 trial data suggest that MC-1 may reduce death or heart attack in high-risk patients undergoing CABG surgery.

John H. Alexander, M.D., M.H.S., of Duke University Medical Center, Duke Clinical Research Institute, Durham, N.C., and colleagues with MEND-CABG II, a phase 3, multicenter, randomized trial, assessed the cardioprotective effect of MC-1 administered before and continued for 30 days after CABG surgery, compared with placebo, in 3,023 intermediate- to high-risk patients undergoing CABG surgery with cardiopulmonary bypass.

The researchers found that the primary efficacy outcome, cardiovascular death or nonfatal heart attack at 30 days, occurred in 140 of 1,510 patients (9.3 percent) in the MC-1 group and 133 of 1,486 patients (9.0 percent) in the placebo group. All-cause death was higher among patients assigned to MC-1 than placebo at 4 days (1.0 percent vs. 0.3 percent) but was similar at 30 days (1.9 percent vs. 1.5 percent). There was no beneficial effect of MC-1 seen in any prespecified subgroup or on other outcomes.

There was no difference in the incidence of postoperative stroke, atrial fibrillation, or kidney function between the two groups. Patients assigned to receive MC-1 and placebo had similar intensive care unit and hospital lengths of stay.

“MEND-CABG II demonstrates that among intermediate- to high-risk patients undergoing CABG surgery, MC-1, 250 mg/d, given immediately before and for 30 days following surgery did not reduce cardiovascular death or nonfatal [heart attack]. Myocardial injury remains a significant problem following CABG surgery. Effective therapies to reduce perioperative morbidity and mortality are needed but remain elusive,” the authors conclude.

Source: JAMA and Archives Journals

Related stories:

Drug-releasing stents linked with decrease in procedures to unblock coronary arteries
The widespread adoption of the use of drug-releasing coronary artery stents into routine practice is associated with a decrease in the need for repeat procedures to unblock coronary arteries and also do not appear to increase the risk of death, compared to bare-metal stents, according to a study in the June 25 issue of JAMA.
'Report cards' don't reflect preventable bypass deaths
While death rate "report cards" indicated low mortality rates after heart bypass surgery, a review of in-hospital deaths in heart bypass patients at Ontario, Canada hospitals found that one-third might have been prevented, researchers report in Circulation: Journal of the American Heart Association.
Patients arriving at hospitals in off hours get slower, less care
Patients hospitalized with heart attacks tend to get faster and more comprehensive care if they arrive during daytime hours, according to a report in Circulation: Journal of the American Heart Association. But, researchers said, variations in care don’t seem to impact in-hospital death rates.
Robot-assisted minimally-invasive CABG surgery
Dr. Robert Poston is a pioneer in the use of robotics for minimally invasive cardiac surgery. He recently joined BMC as chief of cardiac surgery. With his arrival, BMC has become one of only one of 9 hospitals across the country, and the only hospital in Boston, to offer robot-assisted minimally invasive coronary artery bypass, the most advanced treatment available for coronary artery disease (the most common form of heart disease - 16 million Americans have -- and the leading cause of death - 1 million/year --in the U.S.)
Study confirms cardiac surgery drug increases death rate
The largest study to date of a controversial cardiac surgery drug shows it increases death rates and damages kidney function, according Duke University Medical Center researchers.
Downsized heart aids bypass surgery
An estimated one in 20 patients undergoing a common operation to boost blood supply to the heart and to ward off repeat heart attacks may do better if their surgeons also remold the heart to a near normal size, by cutting and suturing together stretched muscle and scar tissue resulting from the initial attack, according to cardiac surgeons at Johns Hopkins.
New insights into chronic inflammation and atherosclerosis
Inflammatory rheumatic disease and smoking independently predict aortic inflammation, suggests study of coronary artery surgery survivors
Rheumatoid arthritis, lupus, and other inflammatory rheumatic diseases are associated with a high rate of death from heart disease. One explanation is a greater susceptibility to atherosclerosis. Although atherosclerosis is linked to inflammation in healthy individuals as well, the mechanism of inflammation and the reason for accelerated atherosclerosis in patients with inflammatory rheumatic disease remain unclear. Does atherosclerosis result from systemic inflammation, a hallmark of these rheumatic diseases, or from local inflammation of vessels?
Genetic 'fingerprint' shown to predict liver cancer's return
Scientists have reached a critical milestone in the study of liver cancer that lays the groundwork for predicting the illness's path, whether toward cure or recurrence. By analyzing the tissue in and around liver tumors, an international research team has identified a kind of genetic "fingerprint" that can help predict if patients' cancers will return. The findings appear in the October 15 advance online edition of the New England Journal of Medicine and were made possible by a large-scale method for revealing genes' activity, which the researchers show can be applied to tissues that have been chemically preserved instead of frozen. This technical triumph promises to unlock biological information within millions of clinical samples previously intractable to genomic study.

News discussion:

Medicine & Health news